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BACKGROUND: There is evidence that prostate cancer (PC) screening with prostate-specific antigen (PSA) serum test decreases PC
mortality, but screening has adverse effects, such as a high false-positive (FP) rate. We investigated the proportion of FPs in a
population-based randomised screening trial in Finland.
METHODS: Finland is the largest centre in the European Randomized Study of Screening for Prostate Cancer. We have completed
three screening rounds with a 4-year screening interval (mean follow-up time 9.2 years) using a PSA cutoff level of 4.0ngml
 1;i n
addition, men with PSA 3.0–3.9 and a positive auxiliary test were referred. An FP result was defined as a positive screening result
without cancer in biopsy within 1 year from the screening test.
RESULTS: The proportion of FP screening results varied from 3.3 to 12.1% per round. Of the screened men, 12.5% had at least one FP
during three rounds. The risk of next-round PC following an FP result was 12.3–19.7 vs 1.4–3.7% following a screen-negative result
(depending on the screening round), risk ratio 3.6–9.9. More than half of the men with one FP result had another one at a
subsequent screen. Men with an FP result were 1.5 to 2.0 times more likely to not participate in subsequent rounds compared with
men with a normal screening result (21.6–29.6 vs 14.0–16.7%).
CONCLUSION: An FP result is a common adverse effect of PC screening and affects at least every eighth man screened repeatedly, even
when using a relatively high cutoff level. False-positive men constitute a special group that receives unnecessary interventions but may
harbour missed cancers. New strategies are needed for risk stratification in PC screening to minimise the proportion of FP men.
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Prostate cancer (PC) is the most common cancer in most
industrialised countries (Parkin et al, 2005). Its incidence
increased steadily from the 1980s onwards, as the increased use
of transurethral resection of the prostate for benign prostatic
hyperplasia (BPH) resulted in more (incidental) PC diagnoses
(Merrill et al, 1999). A steep rise in the incidence of PC was
observed in the 1990s when the prostate-specific antigen (PSA) test
as a diagnostic tool was adapted widely (Welch and Albertsen,
2009). Lately, the incidence of PC has been decreasing in many
countries (Welch and Albertsen, 2009).
Screening for PC with PSA has become one of the most
controversial public health issues. The two major screening trials
in Europe and in the United States have provided inconsistent
results concerning the mortality effects of PSA-based PC screening
(Andriole et al, 2009; Schro ¨der et al, 2009). Although it is essential
to determine mortality and the quality-of-life effects of screening,
it is also important to evaluate the sensitivity and specificity of the
screening test to ensure best possible screening protocol, that is,
maximise the benefits and minimise the harms of screening. The
proportion of false-positive (FP) screening results indicates one
aspect of adverse effects of screening, in addition to overdiagnosis
and overtreatment.
The FP results are related to the specificity of the screening test.
Specificity represents the ability of a test or test protocol to identify
those free of the target disorder. Specificity is calculated as the
ratio of the frequency of the true negative results (those with a
negative test and without the target disease) to the sum of the
frequencies of the true negatives and FPs (those with a positive test
but free of the disease). Hence, the proportion of FP results is
1-specificity.
The FP screening results are common in PC screening, as PSA is
an organ-specific but not a disease-specific marker (Stenman et al,
2000). It has been previously reported that B70% of men with
elevated PSA do not have PC (Catalona et al, 1994; Schro ¨der et al,
1998). The proportion of FP results is likely to increase with age, as
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sprostatic diseases, such as chronic prostatitis and BPH, become
more common (Koskima ¨ki et al, 1998; Rhodes et al, 1999; Wright
et al, 2002). The proportion of FP results has been estimated to be
7–8% (Lafata et al, 2004; Ma ¨a ¨tta ¨nen et al, 2007) per screen (with
1 year of follow-up after the test). In repeated screening, the
cumulative proportion of FP results was recently estimated at
10.4% with four PSA tests and over 3 years of follow-up (Croswell
et al, 2009).
The purpose of our study was to assess the proportion of FP
results in a population-based randomised controlled trial in
Finland during three screening rounds. We evaluated whether
men with an FP result are at greater risk of decreased screening
compliance, subsequent PC, or repeated FP result(s). We also
investigated how many biopsies men with FP results undergo and
whether the use of medication for BPH affects FP rates.
MATERIALS AND METHODS
The Finnish Prostate Cancer Screening Study is the largest
component of the European Randomized Study of Screening for
Prostate Cancer (ERSPC), which is a multicentre randomised trial.
The Finnish trial comprises 80255 men born during 1929–1944
(aged 55, 59, 63 or 67 years at entry) and residing either in the
Helsinki or Tampere metropolitan area. Men with a previous PC
diagnosis were excluded. Subjects were identified from the Finnish
Population Registry. A random sample of 8000 men was allocated
to the screening arm annually during 1996–1999 and the
remaining men formed the control group that received no
interventions and was not contacted either. This analysis covered
only the screened men.
The men in the screening arm were sent an invitation letter
along with a brief overview of the trial, a questionnaire about
urological symptoms, as well as a family history of PC, previous
PSA tests and an informed consent form.
The men in the screening arm were invited to give a blood
sample at a local cancer society clinic in Helsinki or Tampere. Men
with PSA X4ngml
 1 were referred to a urological clinic for
diagnostic examinations, including digital rectal examination
(DRE), transrectal ultrasound and biopsy. Initially, a sextant
biopsy was used, but this was increased to 10–12 biopsy cores in
2002. Men with a PSA level of 3.0–3.9ngml
 1 were referred to an
additional test, which was DRE during 1996–1998 and since 1999 a
free/total PSA (F/T PSA) ratio with a cutoff point of 16%. Men with
a suspicious DRE or F/T PSA ratio o16% were referred to
diagnostic examinations similar to those with PSA X4.0ngml
 1.
All the laboratory analyses were carried out at the Department of
Clinical Chemistry, Helsinki University Hospital. The serum
concentrations of total PSA were analysed by both Hybritech
(Beckman Coulter, Inc., Brea, CA, USA) Tandem-E and Wallac Delfia
(Wallac, Turku, Finland) assays. The free/total PSA ratio was
determined with the Wallac ProStatus (Wallac) free/total PSA assay.
The men in the screening arm were then re-invited in a similar
manner 4 and 8 years after the first screen to the second and third
screening rounds (though men older than 71 years of age were no
longer invited because the core age group in the protocol was
55–69 years of age). The first screening round was carried out
during 1996–1999, the second during 2000–2003 and the third
during 2004–2007. The common closing date of follow-up was 31
December 2007 with a mean follow-up of 9.2 years. All the men in
the screening arm were invited to each round regardless of their
participation in the previous round(s). Men diagnosed with PC were
not re-invited, and neither were men who had emigrated from the
study area or had died. Information on vital status and place of
residence was obtained from the Population Register Centre.
Diagnosis of PC was based on histopathological examination.
A re-biopsy within 2 months was indicated if the primary
histopathological diagnosis was prostatic intraepithelial neoplasia,
atypical small acinar proliferation or unconfirmed suspicion of PC,
or if the PSA level was X10ngml
 1. The decision of re-biopsying a
patient after a negative biopsy was made by the attending
physician, who did not always comply with the protocol of the
screening trial. Therefore, some re-biopsies were performed with
less strict criteria and some postponed further than protocol-
defined time frames. The definition of an FP result was a positive
screening result (based on both total PSA and either DRE or free/
total PSA ratio) and consequent diagnostic work-up with no
histopathological diagnosis of PC in the biopsy within 1 year from
the PSA test. The men who had a positive screening result but did
not undergo biopsy according to the screening protocol were not
analysed in this study.
Data on cancers detected outside the screening protocol were
obtained from the nationwide, population-based Finnish Cancer
Registry, which has 99% coverage of all solid cancers diagnosed in
Finland (Teppo et al, 1994). Information on cancer incidence as
well as vital status was available until the end of 2007. Data on BPH
medication (finasteride or alpha blockers) use at the time of
screening (during 1996–2004) were obtained by linking the study
population to the prescription drug database of the Social
Insurance Institution of Finland (SII, http://www.kela.fi/). The SII
is a governmental agency providing reimbursements to the Finnish
citizens for the cost of drugs prescribed by physicians (with the
exception of hospital in-patients).
The 95% confidence intervals (CIs) for risks and proportions
were calculated on the basis of basic s.e. formulas. A generalised
linear model for binomial distribution with a logarithmic link
function was used to calculate risk ratios (RRs) and their 95% CIs.
The events were FP screening results and diagnosis of PC, with RRs
indicating relative frequencies of outcomes in the groups to be
compared. Statistical analyses were performed using Stata 8.2
(StataCorp, College Station, TX, USA).
RESULTS
Out of 30195 men in the screening arm, 23771 (78.7%)
participated in at least one screening round, and 10327 men
(52.1% of those invited to all rounds) participated in all the three
rounds.
Altogether, 1611 cancers were detected by screening, of which
543 were in the first round with a detection rate (DR) of 2.6%, 613
(DR 3.3%) in the second and 455 (DR 3.6%) in the third. The
overall risk for an FP result was 6.4% in the first round, 8.0% in the
second and 7.8% in the third. The risk of an FP result varied from
3.3 to 12.1% per round, depending on the screening round and age
(Table 1). When men of similar age at screening were compared,
the proportion of FP results was lower at repeat screening
compared with the first round.
Of the men with a screen-positive result in the first round, 67.3%
turned out to be FP and 27.5% were diagnosed with PC (5.2% of
screen-positive men were not biopsied according to the protocol).
In the second round, 64.6% of the screen-positive findings were FP
and 26.6% PC, whereas in the third round 60.7% were FP and
27.7% PC. There was little variation by age (results not shown).
Of the 23771 men who participated at least once during the
three rounds, 12.5% (CI 12.1–12.9) had at least one FP result. The
proportion of men with at least one FP result during the screening
programme increased consistently with age from 9.0% in the
youngest age cohort to 15.7% in the oldest age cohort (with only
two screening rounds). Of the 10327 men who participated in all
three rounds, 1193 (11.6%, CI 10.9–12.2%) had at least one FP
result. Of them, 1.2% (CI 1.0–1.4%) had an FP result in all three
rounds, 2.8% (CI 2.5–3.1%) had it twice and 7.6% (CI 7.1–8.1%)
had it once during the three rounds.
The risk of next-round PC diagnosis was 12.3–19.7% following
an FP result vs 1.4–3.7% following a screen-negative result, RR
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s3.6–9.9 (age-stratified risks, RRs and their CI presented in
Table 2). There were 128 men who had FP in the first round and
were diagnosed with PC in the second round – 78.1% of the
cancers were localised and of low grade (T1-2NxM0 and Gleason
score o7), 13.3% were localised with Gleason score 7, and 8.6%
were advanced (T3-4NxM0 or TxNxM1 or Gleason score X8). In
the men with a negative screening result in the first round and a
screen-detected PC in the second round, the corresponding
numbers were 77.5, 13.2 and 9.3%. Similarly, there were 77
cancers in the third round in those men who had FP in the second
round; 57.1% were localised and of low grade (60.9% in the first
round screen negatives), 29.9% were localised with Gleason score 7
(26.9%), and 13.0% were advanced (12.2%).
More than half of the men with one FP result had another in a
subsequent round, whereas men with normal PSA levels had a 4.8–
5.4% risk of next-round FP result (Table 2). Men with an FP result
were 1.5–2.0 times more likely to not participate in subsequent
rounds compared with men with normal screening results (21.6–
29.6 vs 14.0–16.7%).
In the first round, moderately increased PSA concentration
was associated with high probability of FP, whereas high PSA
concentration (X10ngml
 1) was associated with relatively high
probability of PC (Table 3). Towards the third round, the
probability of PC rose in the moderately increased PSA group
and decreased in the high PSA group.
Information on the use of medication for BPH was available for
23319 men. The number of men who had used medication for BPH
(finasteride or alpha blockers or both) at first screen was 785 (3.8%
of participants, mean age 62.5 years vs 60.1 years in men without
BPH medication), at second screen 1870 (10.1% of participants,
mean age 65.9 years vs 63.8 years) and at third screen 460 (14.5%
of participants in the first year of the third round, mean age 67.1
years vs 66.3 years). The men with BPH medication had roughly
twice the risk for FP result compared with men without BPH
medication: risk for FP was 14.0 vs 6.1% in the first round, 13.4 vs
7.4% in the second round and 11.7 vs 8.5% in the third round. Age-
adjusted first round RR was 1.9 (CI 1.5–2.2, Po0.001), second
round RR was 1.6 (CI 1.4–1.8, Po0.001) and third round RR was
Table 1 Screening results by age and screening round
Screen negative (%) False positive (%) Prostate cancer (%) Not biopsied (%) Total
Round I
55 years 6146 (95.2) 210 (3.3) 76 (1.2) 21 (0.3) 6453
59 years 5136 (92.5) 274 (4.9) 130 (2.3) 12 (0.2) 5552
63 years 4143 (87.6) 397 (8.4) 153 (3.2) 35 (0.7) 4728
67 years 3387 (83.5) 450 (11.1) 184 (4.5) 35 (0.9) 4056
Total 18812 (90.5) 1331 (6.4) 543 (2.6) 103 (0.5) 20789
Round II
59 years 5700 (92.4) 313 (5.1) 115 (1.9) 39 (0.6) 6167
63 years 4464 (88.0) 401 (7.9) 158 (3.1) 48 (0.9) 5071
67 years 3426 (84.9) 372 (9.2) 181 (4.5) 58 (1.4) 4037
71 years 2719 (81.5) 403 (12.1) 159 (4.8) 57 (1.7) 3338
Total 16309 (87.6) 1489 (8.0) 613 (3.3) 202 (1.1) 18613
Round III
63 years 4833 (89.5) 352 (6.5) 157 (2.9) 59 (1.1) 5401
67 years 3618 (86.5) 334 (8.0) 164 (3.9) 66 (1.6) 4182
71 years 2645 (83.8) 312 (9.9) 134 (4.2) 66 (2.1) 3157
Total 11096 (87.1) 998 (7.8) 455 (3.6) 191 (1.5) 12740
Total 46217 (88.6) 3818 (7.3) 1611 (3.1) 496 (1.0) 52142
Non-participants omitted.































55 years 14.1 1.4 9.9 (6.1–16.1) 50.0 4.1 12.2 (9.8–15.1) 27.8 16.4 1.7 (1.3–2.2)
59 years 15.2 2.4 6.3 (4.3–9.4) 64.0 5.5 11.6 (9.8–13.7) 21.6 14.3 1.5 (1.2–1.9)
63 years 19.7 3.2 6.2 (4.5–8.5) 53.6 6.0 9.0 (7.5–10.7) 26.8 14.5 1.8 (1.5–2.2)
67 years 14.2 3.7 3.9 (2.7–5.5) 62.5 7.1 8.8 (7.4–10.4) 27.3 14.0 1.9 (1.6–2.3)
Total 16.0 2.5 6.5 (5.4–7.8) 58.3 5.4 10.7 (9.8–11.7) 26.0 15.0 1.7 (1.6–1.9)
Round 2/Round 3
59 years 12.9 2.1 6.2 (4.0–9.6) 52.0 4.3 12.0 (9.8–14.6) 29.3 16.7 1.8 (1.4–2.1)
63 years 12.3 3.4 3.6 (2.4–5.3) 59.1 4.5 13.3 (11.0–16.0) 29.6 14.6 2.0 (1.7–2.4)
67 years 13.6 3.0 4.5 (3.0–6.7) 58.7 5.9 10.0 (8.3–12.1) 29.3 16.3 1.8 (1.5–2.2)
Total 12.9 2.8 4.7 (3.7–5.9) 57.0 4.8 12.0 (10.7–13.4) 29.4 15.9 1.8 (1.7–2.1)
Abbreviations: PC¼prostate cancer; FP¼false-positive screening result; RR¼risk ratio; CI¼confidence interval.
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s1.3 (CI 1.0–1.8, P-value¼0.04). There was no increased risk for
PC, as the risk in men with BPH medication vs men without BPH
medication was 2.4 vs 2.6% in the first round (age-adjusted RR 0.8,
CI 0.5–1.2, P-value¼0.20), 3.8 vs 3.2% in the second round
(age-adjusted RR 1.0, CI 0.8–1.3, P-value¼0.99) and 7.2 vs 4.7% in
the third round (age-adjusted RR 1.4, CI 1.0–2.0, P-value¼0.08).
In the first round, men who were diagnosed with PC underwent
on average 1.16 biopsies before diagnosis – that is, every sixth man
underwent on average two biopsies. Men with an FP result had 1.30
biopsies in the follow-up time, that is, every third man received
two biopsies. In the second round, men with PC had 1.13 biopsies
and men with FP had 1.25 biopsies. These numbers decreased in
the third round to 1.05 and 1.11, respectively. The maximum
number of biopsies for an FP man was 7 (4 men) and for a man
with PC 4 (1 man). Of the men with at least one FP result, 6.8% had
three or more biopsies.
Of the 1331 men who had an FP result in the first round, 370
(27.8%) developed a PC in the following 8–11 years (128 were
diagnosed at the second screen, 28 at the third screen and 214
outside the screening protocol). Of these, 73.2% were clinically
localised and of low grade (T1-2NxM0 and Gleason o7). Similarly,
of the 1489 FP men in the second round, 237 (15.9%) were in the
following 4–7 years diagnosed with PC (77 at the third screen, 160
outside the screening protocol, 62.0% localised and of low grade).
Of the 998 FP men in the third round, 26 (2.6%) developed PC later
(in the following p3 years, 38.5% were localised and of low grade).
DISCUSSION
Our results show that FP results affect every eighth man in
repeated screening for PC with PSA even with a relatively high
cutoff level of 4.0ngml
 1. More than a quarter of the men with FP
results are subsequently diagnosed with PC, although most of
these cancers are localised and of low grade and have similar
characteristics as cancers in men with a previous negative
screening test. More than half of these men have persistent
high serum PSA levels resulting in repeated FP results and
biopsies. They are also at high risk of dropping out of subsequent
screening.
The Finnish Prostate Cancer Screening Trial is part of the
ERSPC study. There are some differences between the ERSPC
centres in, for example, the mode of recruitment, screening
interval, invitation procedures and the PSA threshold leading to
biopsy. The Finnish trial is population-based and the largest of the
ERSPC centres. A population-based study design ensures good
generalisability at the population level.
The ERSPC study recently showed preliminary mortality results
indicating a 20% relative decrease in mortality in the screening
arm (Schro ¨der et al, 2009). This was the first evidence for benefits
from screening for PC with PSA. However, as shown by the ERSPC
trial, 1410 men would have to be offered screening and 48 PCs
treated to prevent one PC death during a 9-year period. In
addition, the negative consequences of screening (adverse effects,
including overdiagnosis, overtreatment and costs) still need to be
carefully evaluated to allow assessment of the balance between
benefits and harms before evidence-based decision-making
concerning provision of screening can be made. This analysis
contributes to that requirement.
Our study presents a similar proportion of FP results per
screening episode as a previous Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer Screening Trial study (Lafata et al, 2004),
but also provides longer follow-up and information on the relation
between FP results and several clinically important characteristics,
such as PC, BPH medication, age and PSA level. Cumulative rates
of FP results in repeated screening for several screening modalities
were recently reported from the PLCO trial (Croswell et al, 2009).
The authors showed a risk of 10.4% for at least one FP result in
annual PSA screening during the 3-year screening period. We
found a 12.5% risk for at least one FP result in two to three
successive screening rounds during a 12-year follow-up, but the
probability varied strongly with age. In the youngest age cohort
(screened initially at age 55), the risk was 9.0% and in the oldest
men (first screen at age 67 with only two rounds of screening) it
was 15.7%. As previously noted, the incidence of PSA-elevating
diseases other than PC (prostatitis, BPH) increases with age
(Koskima ¨ki et al, 1998; Rhodes et al, 1999; Wright et al, 2002) and
explains the higher FP proportion in older men. This explanation
is also consistent with the finding that men who used BPH
medication had an increased risk for an FP result, despite the
Table 3 Proportions of men with false-positive results and prostate cancer by serum PSA concentration in the three rounds of the trial




p2.9 or 3.0–3.9 and aux. test   18812 (90.5) — — —
3.0–3.9 and aux. test + 149 (0.7) 142 (95.3) 105 (73.9) 37 (26.1)
4.0–9.9 1527 (7.3) 1440 (94.3) 1110 (77.1) 330 (22.9)
X10.0 301 (1.4) 292 (97.0) 116 (39.7) 176 (60.3)




p2.9 or 3.0–3.9 and aux. test – 16309 (87.6) — — —
3.0–3.9 and aux. test + 232 (1.2) 215 (92.7) 147 (68.4) 68 (31.6)
4.0–9.9 1819 (9.8) 1653 (90.9) 1203 (72.8) 450 (27.2)
X10.0 253 (1.4) 234 (92.5) 139 (59.4) 95 (40.6)




p2.9 or 3.0–3.9 and aux. test – 11096 (87.1) — — —
3.0–3.9 and aux. test + 160 (1.3) 142 (88.8) 88 (62.0) 54 (38.0)
4.0–9.9 1328 (10.4) 1167 (87.9) 813 (69.7) 354 (30.3)
X10.0 156 (1.2) 144 (92.3) 97 (67.4) 47 (32.6)
Total 12740 1453 (11.4) 998 (7.8) 455 (3.6)
Abbreviations: PSA¼prostate-specific antigen; aux. test¼auxiliary test. Auxiliary test: 1996–1998 digital rectal examination, 1999–2007 free/total PSA ratio (cutoff 16%).
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sPSA-lowering effect of finasteride (Etzioni et al, 2005). These men
were also older than men without BPH medication.
In our study, a PSA threshold of 4.0ngml
 1 was used. In
addition, during 1996–1998, men with a suspicious DRE finding
and in 1999–2007 men with PSA 3.0–3.9 and free/total PSA ratio
p16% were referred. The PSA threshold was chosen in 1996 when
the study began. A study from the Prostate Cancer Prevention Trial
reported that 24.7% of men in the placebo group with PSA 2.1–4.0
had PC when biopsied at the end of the study, although 50% of
these men were older than 71 years and all the cancers were stage
T1 (Thompson et al, 2004). In another study with younger subjects
(50–65 years), 11.3% (13 of 115) of men with PSA level 1.1–3.99
and F/T PSA X20% had cancer in biopsy (Rowe et al, 2005). In our
study with men aged 55–71 years, the proportion of PC from those
biopsied varied from 26.6 to 32.9%. If the PSA threshold had been
lower, for example, 2.1–3.9ngml
 1, the proportion of PC in the
biopsied men would probably be smaller, that is, the downside of
the expected improvement in sensitivity would be a decreased
specificity.
A screen-detected cancer was defined as a PC detected within 1
year from the PSA test in a man with a screen-positive result. On
this basis, we defined an FP as a screen-positive result with no PC
diagnosis within 1 year from the PSA test (excluding men without
biopsy). Prostate-specific antigen predicts the development of PC
by several years and there is no clear time as for the optimal
definition of an FP result, but the proportion of de novo cases
relative to those present at the screen can be anticipated to
increase with time since the PSA test. If we had extended our
1-year limit to, for example, 3 years, the number of FP results
would have decreased by 86 (6.5%), 88 (5.9%) and 47 (4.7%) men
in the first, second and third rounds, respectively. These men were
diagnosed with an interval cancer within 1–3 years from the PSA
test. As the proportion of these men out of all FP men was
relatively small (4.7–6.5%), using another definition would not be
likely to materially affect our results.
In cancer screening, FP results are problematic for several
reasons. Biopsies bring discomfort and often pain to the patient
during the procedure (Ma ¨kinen et al, 2002). Waiting for the result
is a psychological strain, which can have negative effects for at
least a year even after a negative biopsy result (Fowler et al, 2006).
The economic impact of FP results has not been thoroughly
analysed, but these men seem to receive more follow-up
interventions such as PSA testing and re-biopsies, which add to
the costs of screening (Lafata et al, 2004). Biopsy – similar to any
invasive procedure – involves risks for adverse health effects, such
as bleeding, infection or abscess formation (Ma ¨kinen et al, 2002),
although these complications are not very common.
There is previous evidence that FP men undergo more follow-up
testing and biopsies than men with normal PSA (Fowler et al,
2006). Our results show that men with FP results receive more
biopsies than do men who are diagnosed with PC. On average,
every third FP man undergoes two biopsies within 4 years from the
screen. It has been previously reported that the risk of clinically
significant cancer decreases after the second biopsy (Djavan et al,
2003). Our study is likely to underestimate the average number of
biopsies as we have no data on private sector visits and procedures
and it is likely that some of the benign biopsies in the public sector
are not reported to our database.
However, our findings indicate an increased risk for future PC
with a history of one or several FP results. As many as 16% of FP
men were diagnosed with PC in the next round. Most of the PCs
were not aggressive, but, for example, in the third round as many
as 29.9% of cancers were Gleason score 7 and 13% were advanced
(T3-4NxM0 or TxNxM1 or Gleason score 8). Of the first round FP
men, almost a third were diagnosed with PC during the 8–11
follow-up years. The proportion of PC diagnoses among the men
with FP results at the second and third rounds were substantially
lower (15.9 and 2.6%) – most likely because of a shorter follow-up.
As previously mentioned, over 10% of men over 50 years of age
can be diagnosed with PC even with low PSA levels (Rowe et al,
2005). Therefore, if men with an FP result receive more biopsies in
the follow-up period than men with a negative screen, they could
be more likely to receive a PC diagnosis because of more
frequent biopsying. In addition, in 2002 we started using 10–12
core biopsies instead of sextant biopsies, which could increase the
chances of finding small, indolent lesions during the later follow-
up period. Both these factors increase the PC risk in FP men.
When the men were stratified by serum PSA level, it was evident
that at the first (prevalence) screen, high PSA level was clearly
associated with PC and moderately increased serum PSA level with
FP. At the second and third (incidence) screens, these differences
evened out and the positive predictive value of high PSA for PC
decreased. The most likely explanation for these trends is that at
the first screen most of the high PSA cancers were ‘harvested’ from
the study population. Some of them were still detected at the
second screen, but generally the cancers that produce high PSA
were caught at the prevalence screen and few such cases arose de
novo between the screening rounds.
In the PLCO trial, men with an FP result were almost twice more
likely to decline subsequent screening compared with men with a
negative screening result (Ford et al,2 0 0 5 ) .O u rr e s u l t sa r es i m i l a r ,
with RRs varying from 1.5 to 2.0. There might be several reasons
behind this. The FP men could decide not to participate because of
the unpleasant experience of unnecessary biopsy procedures and the
anxiety related to the fear of PC diagnosis. On the other hand, an FP
man could sense relief after a benign biopsy and deem it unnecessary
to participate in the next screening round. Also, receiving a positive
screening result without a confirmed PC diagnosis may erode a man’s
perception of the effectiveness of screening.
These findings emphasise the paradoxical problem of FP results
in PC screening. On the one hand, FP men frequently have
persistently high PSA levels (450% chance of having another FP
result in the next round) and undergo several biopsies. On the
other hand, they are more likely to be diagnosed with PC, either
because of biological processes or more active diagnostic
procedures. New approaches are urgently needed for improved
risk stratification among these men, that is, to predict which of
them may harbour a clinically significant PC, which may have an
insignificant indolent PC and which may have other factors
underlying the elevated PSA level.
There is one weakness in our study. In some cases, the follow-up
time after the third screen was relatively short (p3 years), as the
last men were screened in the end of 2007 and follow-up ended in
2007. Therefore, some post-screening cancers were lacking for the
last screening cohort. However, we believe that the strengths of this
study well outweigh this weakness.
In conclusion, we present data from a prospective randomised
controlled PC screening study spanning 12 years and three screening
rounds. We have analysed the FP screening results during these
rounds and calculated that every eighth man screened is subject to
an FP result at least once in repeat screening. The men who receive
FP results are likely to have a subsequent FP result(s) later if
screened again. Also, these men commonly drop out of subsequent
screening rounds. This poses a difficult equation, as men with FP
results are at increased risk of being diagnosed later with a PC. More
research is needed to balance the sensitivity and specificity of PC
screening to minimise the proportion of FP results.
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